Argentiere Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Argentiere Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-42,000	Closed	-$3.73M	–	4
2019 Q1	$3.73M	Sell	42,000 -1,000	-2%	-$92.7K	1.62%	29
2018 Q4	$3.66M	Buy	43,000 +3,800	+10%	+$361K	1.14%	23
2018 Q3	$3.8M	Buy	39,200 +4,200	+12%	+$419K	0.39%	43
2018 Q2	$3.3M	Sell	35,000 -35,000	-50%	-$3.07M	1.27%	16
2018 Q1	$5.67M	Buy	70,000 +20,000	+40%	+$1.72M	2.42%	8
2017 Q4	$4.46M	Buy	50,000 +5,000	+11%	+$435K	2.75%	6
2017 Q3	$4.19M	Buy	45,000 +2,000	+5%	+$177K	1.61%	14
2017 Q2	$3.9M	Buy	43,000 +2,000	+5%	+$182K	1.31%	12
2017 Q1	$3.6M	Buy	41,000 +10,000	+32%	+$890K	1.45%	16
2016 Q4	$2.57M	Buy	+31,000	New	+$2.67M	1.21%	21
2014 Q4	–	Sell	-22,400	Closed	-$1.62M	–	28
2014 Q3	$1.62M	Hold	22,400	–	–	0.72%	13
2014 Q2	$1.39M	Buy	+22,400	New	+$1.35M	0.63%	11

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Argentiere Capital's BMRN Position: Q2 2019 in Review

Argentiere Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 42,000 shares — an estimated $3.73M sold.

Argentiere Capital first reported a position in BMRN in Q2 2014 and held it in 12 quarters. The position peaked at $5.67M in Q1 2018. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

Argentiere Capital reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Argentiere Capital sold 42,000 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $3.73M.
Argentiere Capital first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 12 quarters.
Argentiere Capital's BioMarin Pharmaceuticals position peaked at $5.67M in Q1 2018.
482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Argentiere Capital's 13F filing for Q2 2019, filed 14 Aug 2019.